Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

Biotechnology Progress

Volumn 21, Issue 6, 2005, Pages 1644-1652

  Hodoniczky, Jason ^a   Yuan, Zhi Zheng ^a   James, David C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CELLS; GLUCOSE; MATHEMATICAL MODELS; MOLECULES; TOXICITY;

ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC); COMPLEMENT-DEPENDENT CYTOTOXICITY (CDC); DEGALACTOSYLATION; OLIGOSACCHARIDE;

MONOCLONAL ANTIBODIES;

BETA 1,4 MANNOSYL GLYCOPROTEIN BETA 1,4 N ACETYLGLUCOSAMINYLTRANSFERASE; BETA-1,4-MANNOSYL-GLYCOPROTEIN BETA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINYLTRANSFERASE; POLYSACCHARIDE; RECOMBINANT PROTEIN; RITUXIMAB; TRASTUZUMAB;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BIOTECHNOLOGY; CELL LINE; CHEMISTRY; CYTOTOXICITY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOLOGY; IN VITRO STUDY; MASS SPECTROMETRY; METABOLISM; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOTECHNOLOGY; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOTOXICITY, IMMUNOLOGIC; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; N-ACETYLGLUCOSAMINYLTRANSFERASES; POLYSACCHARIDES; RATS; RECEPTORS, FC; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

INSECTA;

EID: 28844463354     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp050228w     Document Type: Article

References (43)

1. Manches, O.; Lui, G.; Chaperot, L.; Gressin, R.; Molens, J. P.; Jacob, M. C.; Sotto, J. J.; Leroux, D.; Bensa, J. C.; Plumas, J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101, 949-954.
2. Reff, M. E.; Carner, K.; Chambers, K. S.; Chinn, P. C.; Leonard, J. E.; Raab, R.; Newman, R. A.; Hanna, N.; Anderson, D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83, 435-445.
3. Di Gaetano, N.; Cittera, E.; Nota, R.; Vecchi, A.; Grieco, V.; Scanziani, E.; Botto, M.; Introna, M.; Golay, J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171, 1581-1587.
4. Dall'Ozzo, S.; Tartas, S.; Paintaud, G.; Cartron, G.; Colombat, P.; Bardos, P.; Watier, H.; Thibault, G. Rituximab-dependent cytotoxicity by natural killer cells: influence of Fc gamma RIIIa polymorphism on the concentration-effect relationship. Cancer Res. 2004, 64, 4664-4669.
5. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene. Blood 2002, 99, 754-758.
6. Golay, J.; Lazzari, M.; Facchinetti, V.; Bernasconi, S.; Borleri, G.; Barbui, T.; Rambaldi, A.; Introna, M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001, 98, 3383-3389.
7. Golay, J.; Zaffaroni, L.; Vaccari, T.; Lazzari, M.; Borleri, G. M.; Bernasconi, S.; Tedesco, F.; Rambaldi, A.; Introna, M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95, 3900-3908.
8. Idusogie, E. E.; Wong, P. Y.; Presta, L. G.; Gazzano-Santoro, H.; Totpal, K.; Ultsch, M.; Mulkerrin, M. G. Engineered antibodies with increased activity to recruit complement. J. Immunol. 2001, 166, 2571-2575.
9. Shields, R. L.; Namenuk, A. K.; Hong, K.; Meng, Y. G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J. A.; Presta, L. G. High-resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276, 6591-6604.
10. Presta, L. G.; Shields, R. L.; Namenuk, A. K.; Hong, K.; Meng, Y. G. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. 2002, 30, 487-490.
11. Davies, J.; Jiang, L.; Pan, L. Z.; LaBarre, M. J.; Anderson, D.; Reff, M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 2001, 74, 288-294.
12. Shields, R. L.; Lai, J.; Keck, R.; O'Connell, L. Y.; Hong, K.; Meng, Y. G.; Weikert, S. H.; Presta, L. G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc gamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277, 26733-26740.
13. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466-3473.
14. Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17, 176-180.
15. Niwa, R.; Shoji-Hosaka, E.; Sakurada, M.; Shinkawa, T.; Uchida, K.; Nakamura, K.; Matsushima, K.; Ueda, R.; Hanai, N.; Shitara, K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004, 64, 2127-2133.
16. Ripka, J.; Adamany, A.; Stanley, P. Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Arch. Biochem. Biophys. 1986, 249, 533-545.
17. Mori, K.; Kuni-Kamochi, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yamano, K.; Imai, H.; Kanda, Y.; Niwa, R.; Iida, S.; Uchida, K.; Shitara, K.; Satoh, M. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol. Bioeng. 2004, 88, 901-908.
18. Yamane-Ohnuki, N.; Kinoshita, S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 2004, 87, 614-622.
19. Ikeda, Y.; Taniguchi, N. Enzymatic properties and biological functions of beta 1,4-N-acetylglucosaminyltransferase III. Trends Glycosci. Glycotechnol. 2001, 13, 167-176.
20. Ikeda, Y.; Koyota, S.; Ihara, H.; Yamaguchi, Y.; Korekane, H.; Tsuda, T.; Sasai, K.; Taniguchi, N. Kinetic basis for the donor nucleotide-sugar specificity of beta 1,4-N-acetylglucosaminyltransferase III. J. Biochem. 2000, 128, 609-619.
21. Nishikawa, A.; Ihara, Y.; Hatakeyama, M.; Kangawa, K.; Taniguchi, N. Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine-beta-D- mannoside beta-1,4-N-acetylglucosaminyltransferase-III from rat kidney. J. Biol. Chem. 1992, 267, 18199-18204.
22. Zheng, Y. Z.; Greenfield, P. F.; Reid, S. Optimized production of recombinant bluetongue core-like particles produced by the baculovirus expression system. Biotechnol. Bioeng. 1999, 65, 600-604.
23. Bigge, J. C.; Patel, T. P.; Bruce, J. A.; Goulding, P. N.; Charles, S. M.; Parekh, R. B. Nonselective and efficient fluorescent labeling of glycans using 2-aminobenzamide and anthranilic acid. Anal. Biochem. 1995, 230, 229-238.
24. Guile, G. R.; Rudd, P. M.; Wing, D. R.; Prime, S. B.; Dwek, R. A. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 1996, 240, 210-226.
25. Koene, H. R.; Kleijer, M.; Algra, J.; Roos, D.; von dem Borne, A. E.; de Haas, M. Fc gamma RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gamma RIIIa, independently of the Fc gamma RIIIa-48L/R/H phenotype. Blood 1997, 90, 1109-1114.
26. Masuda, K.; Yamaguchi, Y.; Kato, K.; Takahashi, N.; Shimada, I.; Arata, Y. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 2000, 473, 349-357.
27. Boyd, P. N.; Lines, A. C.; Patel, A. K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 1995, 32, 1311-1318.
28. Wright, A.; Morrison, S. L. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 1998, 160, 3393-3402.
29. Savvidou, G.; Klein, M.; Grey, A. A.; Dorrington, K. J.; Carver, J. P. Possible role for peptide-oligosaccharide interactions in differential oligosaccharide processing at asparagine-107 of the light chain and asparagine-297 of the heavy chain in a monoclonal IgG1 kappa. Biochemistry 1984, 23, 3736-3740.
30. Brisson, J. R.; Carver, J. P. The relation of three-dimensional structure to biosynthesis in the N-linked oligosaccharides. Can. J. Biochem. Cell Biol. 1983, 61, 1067-1078.
31. Krapp, S.; Mimura, Y.; Jefferis, R.; Huber, R.; Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325, 979-989.
32. Mimura, Y.; Sondermann, P.; Ghirlando, R.; Lund, J.; Young, S. P.; Goodall, M.; Jefferis, R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J. Biol. Chem. 2001, 276, 45539-45547.
33. Wormald, M. R.; Rudd, P. M.; Harvey, D. J.; Chang, S. C.; Scragg, I. G.; Dwek, R. A. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997, 36, 1370-1380.
34. Sondermann, P.; Huber, R.; Oosthuizen, V.; Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gamma RIII complex. Nature 2000, 406, 267-273.
35. Radaev, S.; Motyka, S.; Fridman, W. H.; Sautes-Fridman, C.; Sun, P. D. The structure of a human type III Fc gamma receptor in complex with Fc. J. Biol. Chem. 2001, 276, 16469-16477.
36. Lund, J.; Takahashi, N.; Pound, J. D.; Goodall, M.; Jefferis, R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 1996, 157, 4963-4969.
37. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 2005, 21, 11-16.
38. Fukuta, K.; Abe, R.; Yokomatsu, T.; Omae, F.; Asanagi, M.; Makino, T. Control of bisecting GlcNAc addition to N-linked sugar chains. J. Biol. Chem. 2000, 275, 23456-23461.
39. Umana, P.; Jean-Mairet, J.; Bailey, J. E. Tetracycline-regulated overexpression of glycosyltransferases in Chinese hamster ovary cells. Biotechnol. Bioeng. 1999, 65, 542-549.
40. Stanley, P.; Sundaram, S.; Tang, J.; Shi, S. Molecular analysis of three gain-of-function CHO mutants that add the bisecting GlcNAc to N-glycans. Glycobiology 2005, 15, 43-53.
41. Raju, T. S.; Briggs, J. B.; Borge, S. M.; Jones, A. J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000, 10, 477-486.
42. van der Kolk, L. E.; Grillo-Lopez, A. J.; Baars, J. W.; Hack, C. E.; van Oers, M. H. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 2001, 115, 807-811.
43. Hills, A. E.; Patel, A.; Boyd, P.; James, D. C. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol. Bioeng. 2001, 75, 239-251.